sorafenib has been researched along with u 0126 in 18 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (u 0126) | Trials (u 0126) | Recent Studies (post-2010) (u 0126) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,816 | 2 | 1,213 |
| Protein | Taxonomy | sorafenib (IC50) | u 0126 (IC50) |
|---|---|---|---|
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.29 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.25 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.07 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 0.2816 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.2529 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, QZ; Illgen, K; Keng, YF; Khazak, V; Lu, Y; Menon, SR; Sakamuri, S; Schabbert, S; Weber, L | 1 |
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Jin, H; Liang, L; Niu, Y; Peng, Y; Sun, J; Wang, C; Xie, B; Xu, F; Xu, P; Zhang, H | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Colombi, M; Kiser, KF; Moroni, C | 1 |
| Flaherty, KT; Garbe, C; Kulms, D; Lasithiotakis, KG; Maczey, E; Meier, FE; Schittek, B; Sinnberg, TW | 1 |
| Becker, JC; Hofmeister, V; Houben, R; Noelke, C; Schrama, D; Voigt, H | 1 |
| Braun, M; Buness, A; Conrad, J; Falk, CS; Krapfenbauer, U; Kuner, R; Lund, P; Mang-Fatehi, S; Poustka, A; Ruschhaupt, M; Schäfer, R; Sers, C; Stelniec, I; Sueltmann, H | 1 |
| Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
| Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Deville, A; Giacchero, D; Lacour, JP; Ortonne, JP; Passeron, T; Ségalen, C; Thyss, A | 1 |
| Corey, SJ; Park, BJ; Whichard, ZL | 1 |
| Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ; Xiong, MJ | 1 |
| Chen, W; Deng, J; Li, X; Wu, XY; Zhang, L; Zhang, YN; Zhong, CJ; Zhong, N | 1 |
| Graham, RM; Thompson, JW; Webster, KA | 1 |
| Anderson, DG; Conte, D; Fischer, A; Hough, S; Kennedy, Z; Li, Y; Moore, J; Mou, H; Park, A; Pomyen, Y; Song, CQ; Thorgeirsson, S; Wang, XW; Weng, Z; Xue, W; Yin, H; Zender, L | 1 |
| Avenia, N; Ayroldi, E; Cannarile, L; Cari, L; Marchetti, MC; Moretti, S; Petrillo, MG; Puxeddu, E; Riccardi, C; Ricci, E; Ronchetti, S | 1 |
| Bu, Y; Chang, F; Jia, F; Jia, Q; Jiang, S; Liao, X; Ning, P; Song, G; Xiao, X; Zhang, M | 1 |
1 review(s) available for sorafenib and u 0126
| Article | Year |
|---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
17 other study(ies) available for sorafenib and u 0126
| Article | Year |
|---|---|
Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator.
Topics: Animals; Cell Division; Cell Line; CHO Cells; Cricetinae; Drug Design; Enzyme Inhibitors; Kinetics; Mitogen-Activated Protein Kinases; Molecular Structure; Piperidines; Pyridines; ras Proteins; Recombinant Proteins; Signal Transduction; Structure-Activity Relationship | 2004 |
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Discovery of 3-benzyl-1,3-benzoxazine-2,4-dione analogues as allosteric mitogen-activated kinase kinase (MEK) inhibitors and anti-enterovirus 71 (EV71) agents.
Topics: Allosteric Regulation; Antiviral Agents; Cell Line; Drug Discovery; Enterovirus A, Human; Extracellular Signal-Regulated MAP Kinases; Humans; Protein Kinase Inhibitors | 2016 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants.
Topics: Aminacrine; Benzenesulfonates; Butadienes; Cell Transformation, Neoplastic; Clone Cells; Frameshift Mutation; Genes, Dominant; Genes, Recessive; Hematopoiesis; Humans; Interleukin-3; MAP Kinase Kinase Kinases; Mutagenesis, Insertional; Neoplastic Stem Cells; Niacinamide; Nitriles; Nitrogen Mustard Compounds; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Retroviridae; Sorafenib; STAT5 Transcription Factor; Transfection | 2006 |
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Topics: Androstadienes; Apoptosis; Benzenesulfonates; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; Flavonoids; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mitogen-Activated Protein Kinase Kinases; Morpholines; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sirolimus; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Wortmannin | 2008 |
MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib.
Topics: Antibodies; Antigens, Neoplasm; Benzenesulfonates; Butadienes; CD28 Antigens; CD3 Complex; Epitopes; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Phytohemagglutinins; Protein Kinase Inhibitors; Pyridines; Receptors, Antigen, T-Cell; Signal Transduction; Sorafenib; T-Lymphocytes; Tetradecanoylphorbol Acetate | 2009 |
Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Butadienes; Colonic Neoplasms; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; HCT116 Cells; HLA-A2 Antigen; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib | 2009 |
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Butadienes; Cell Survival; Dacarbazine; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fatal Outcome; Female; Genes, ras; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Niacinamide; Nitriles; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Phosphorylation; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Sorafenib; Treatment Outcome | 2011 |
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Epothilones; Female; Humans; Morpholines; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Pyrimidines; Signal Transduction; Sirolimus; Sorafenib; Tamoxifen; Thiazoles | 2012 |
Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; K562 Cells; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib; U937 Cells; Up-Regulation | 2013 |
Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib | 2014 |
Inhibition of the vacuolar ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Butadienes; Cell Hypoxia; Enzyme Inhibitors; Gene Knockdown Techniques; Heterografts; Humans; Hydrogen-Ion Concentration; Macrolides; MAP Kinase Signaling System; MCF-7 Cells; Membrane Proteins; Mice; Neoplasm Metastasis; Niacinamide; Nitriles; Phenylurea Compounds; Proto-Oncogene Proteins; Sorafenib; Tumor Burden; Vacuolar Proton-Translocating ATPases | 2014 |
Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Topics: Animals; Benzimidazoles; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; CRISPR-Cas Systems; Cytoskeletal Proteins; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Neurofibromatosis 1; Genome-Wide Association Study; Hepatocytes; High-Throughput Nucleotide Sequencing; HMGA Proteins; HMGA2 Protein; Humans; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Membrane Glycoproteins; Mice; Mice, Knockout; Mice, Nude; Mitogen-Activated Protein Kinases; Nerve Tissue Proteins; Niacinamide; Nitriles; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridones; Pyrimidinones; ras Proteins; Real-Time Polymerase Chain Reaction; Receptors, Cell Surface; Sequence Analysis, DNA; Sorafenib; Survival Analysis; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2017 |
Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.
Topics: Butadienes; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mitogen-Activated Protein Kinases; Models, Biological; Nitriles; Phosphorylation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms; Transcription Factors; Transcriptional Activation; Up-Regulation; Vemurafenib | 2018 |
CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; Connective Tissue Growth Factor; Down-Regulation; Drug Resistance, Neoplasm; Feedback; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxaliplatin; Protein Kinase Inhibitors; RNA, Messenger; Sorafenib; Up-Regulation | 2019 |